Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to boost lung cancer treatment

NCT ID NCT06116786

Disease control Sponsor: Johnson & Johnson Enterprise Innovation Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find a safe and tolerable dose. About 126 participants will be enrolled. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JNJ-86974680 (an A2a receptor antagonist) and cetrelimab (an immunotherapy drug)
What this could lead to
If successful, this could help identify a safe dose of a new drug combination that may improve treatment options for advanced lung cancer.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to show benefit in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

67 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC) * Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed * Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\]) * Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy * For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy * For Cohort C of Part 2: Treatment naïve * Adequate organ function Exclusion Criteria: * Active central nervous system (CNS) disease involvement * Active autoimmune disease * Active infection * History of solid organ or hematologic stem cell transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Charite Research Organisation GmbH

    Berlin, 12203, Germany

  • City of Hope 1

    Newnan, Georgia, 30265, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

    New York, New York, 10032, United States

  • Hosp Univ Vall D Hebron

    Barcelona, 8035, Spain

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041, Spain

  • Hosp. Univ. I Politecni La Fe

    Valencia, 46026, Spain

  • Hosp. Univ. Quiron Dexeus

    Barcelona, 08028, Spain

  • Next Virginia

    Fairfax, Virginia, 22031, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14203, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, 03722, South Korea

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • Universitaetsklinikum Giessen und Marburg GmbH

    Giessen, 35392, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.